{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:45:53Z","timestamp":1791834353708,"version":"4.3.4"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bristol Myers Squibb"},{"DOI":"10.13039\/100000102","name":"Health Resources and Services Administration","doi-asserted-by":"publisher","award":["234-2005-370011C"],"award-info":[{"award-number":["234-2005-370011C"]}],"id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Belatacept is approved for the prophylaxis of organ rejection in Epstein-Barr virus (EBV)-seropositive kidney transplant recipients and is associated with a risk of post-transplant lymphoproliferative disorder (PTLD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from the Organ Procurement and Transplantation Network were used to examine patterns of belatacept use, describe patient characteristics, and estimate risk of PTLD in EBV-seropositive, kidney-only transplant recipients receiving belatacept- or calcineurin inhibitor (CNI)-based immunosuppression as part of US Food and Drug Administration-mandated safety monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During the study period (June 15, 2011\u2013June 14, 2016), 94.9% (1631\/1719) of belatacept-treated and 89.7% (59,992\/66,905) of CNI-treated patients with known EBV serostatus were EBV seropositive. Among EBV-seropositive patients, 50.2% (belatacept) and 56.8% (CNI) received a standard criteria donor kidney, 59.5% and 18.7% received basiliximab induction, and 22.9% and 50.8% received antithymocyte globulin induction. PTLD developed in nine belatacept-treated patients (two with central nervous system [CNS] involvement) and 225 CNI-treated patients (nine with CNS involvement). Four and 81 patients, respectively, died due to PTLD. Kaplan\u2013Meier analysis did not show a significant between-group difference in PTLD estimated incidence rates within 5 years (0.70% versus 0.48%, respectively; p = 0.18). Additionally, estimated PTLD incidence was not significantly different between treatment groups in a propensity score matched cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The majority of adult kidney-only transplant recipients treated with belatacept in routine clinical practice are EBV seropositive. In this study, the risk of PTLD in these patients, while higher than for CNI-based immunosuppression, remained low after adjusting for differences in patient characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec005\">\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      These studies are registered at ClinicalTrials.gov:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01670058\" xlink:type=\"simple\">NCT01670058<\/jats:ext-link>\n                      and\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01656343\" xlink:type=\"simple\">NCT01656343<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0311935","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T15:09:21Z","timestamp":1736521761000},"page":"e0311935","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Patterns of belatacept use and risk of post-transplant lymphoproliferative disorder in US kidney transplant recipients: An analysis of the Organ Procurement and Transplantation Network database"],"prefix":"10.1371","volume":"20","author":[{"given":"Wida S.","family":"Cherikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzuyung Douglas","family":"Kou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Foutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8728-3124","authenticated-orcid":true,"given":"Andres","family":"Gomez-Caminero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"issue":"12","key":"pone.0311935.ref001","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.4049\/jimmunol.1390055","article-title":"Calcineurin inhibitors: 40 years later, can\u2019t live without","volume":"191","author":"JR Azzi","year":"2013","journal-title":"J Immunol"},{"issue":"9","key":"pone.0311935.ref002","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1034\/j.1600-6143.2002.20902.x","article-title":"Cardiovascular toxicities of immunosuppressive agents.","volume":"2","author":"LW Miller","year":"2002","journal-title":"Am J Transplant"},{"issue":"2","key":"pone.0311935.ref003","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"M Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"pone.0311935.ref004","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1517\/14740338.2015.1083974","article-title":"The safety of calcineurin inhibitors for kidney-transplant patients.","volume":"14","author":"P Malvezzi","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"pone.0311935.ref005","first-page":"374","article-title":"Advances in immunosuppression for kidney transplantation: new strategies for preserving kidney function and reducing cardiovascular risk","volume":"32","author":"O Bestard","year":"2012","journal-title":"Nefrologia"},{"issue":"3","key":"pone.0311935.ref006","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1600-6143.2005.00749.x","article-title":"Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties.","volume":"5","author":"CP Larsen","year":"2005","journal-title":"Am J Transplant."},{"issue":"11","key":"pone.0311935.ref007","first-page":"CD010699","article-title":"Belatacept for kidney transplant recipients.","author":"P Masson","year":"2014","journal-title":"Cochrane Database Syst Rev."},{"issue":"11","key":"pone.0311935.ref008","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1111\/ajt.13830","article-title":"Long-term outcomes in belatacept- versus cyclosporine-treated recipients of extended criteria donor kidneys: final results from BENEFIT-EXT, a phase III randomized study.","volume":"16","author":"A Durrbach","year":"2016","journal-title":"Am J Transplant"},{"issue":"3","key":"pone.0311935.ref009","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1600-6143.2010.03016.x","article-title":"A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study).","volume":"10","author":"A Durrbach","year":"2010","journal-title":"Am J Transplant"},{"issue":"3","key":"pone.0311935.ref010","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).","volume":"10","author":"F Vincenti","year":"2010","journal-title":"Am J Transplant"},{"issue":"4","key":"pone.0311935.ref011","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"F Vincenti","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0311935.ref012","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1111\/j.1600-6143.2006.01540.x","article-title":"Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry.","volume":"6","author":"S Caillard","year":"2006","journal-title":"Am J Transplant."},{"issue":"10","key":"pone.0311935.ref013","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1034\/j.1600-6143.2002.21019.x","article-title":"Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk.","volume":"2","author":"VR Dharnidharka","year":"2002","journal-title":"Am J Transplant"},{"issue":"4","key":"pone.0311935.ref014","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.asjsur.2018.09.002","article-title":"Different causes of early and late-onset post transplant lymphoproliferative disorder in kidney transplantation patients after 2000.","volume":"42","author":"JG Gwon","year":"2019","journal-title":"Asian J Surg."},{"issue":"7","key":"pone.0311935.ref015","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1002\/cam4.3636","article-title":"Cumulative cancer incidence and mortality after kidney transplantation in Japan: A long-term multicenter cohort study","volume":"10","author":"R Imamura","year":"2021","journal-title":"Cancer Med"},{"issue":"4","key":"pone.0311935.ref016","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/tri.12744","article-title":"Post-transplant lymphoproliferative disorder following kidney transplantation: a population-based cohort study","volume":"29","author":"EF Maksten","year":"2016","journal-title":"Transpl Int"},{"issue":"4","key":"pone.0311935.ref017","doi-asserted-by":"crossref","first-page":"437","DOI":"10.18632\/oncotarget.26522","article-title":"A single-center experience of post-transplant lymphomas involving the central nervous system with a review of current literature.","volume":"10","author":"AJJ Velvet","year":"2019","journal-title":"Oncotarget."},{"issue":"7","key":"pone.0311935.ref018","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/tri.12328","article-title":"Comparative analysis of post-transplant lymphoproliferative disorder after kidney transplantation versus hematopoietic stem cell transplantation","volume":"27","author":"JH Yoon","year":"2014","journal-title":"Transpl Int"},{"issue":"3","key":"pone.0311935.ref019","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11899-013-0162-5","article-title":"Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies.","volume":"8","author":"Z Al-Mansour","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"issue":"3","key":"pone.0311935.ref020","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1600-6143.2011.03976.x","article-title":"Summary of the US FDA approval of belatacept.","volume":"12","author":"P Archdeacon","year":"2012","journal-title":"Am J Transplant."},{"key":"pone.0311935.ref021","article-title":"EPAR","author":"Nulojix","journal-title":"European Medicines Agency Web site"},{"issue":"11","key":"pone.0311935.ref022","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician.","volume":"35","author":"L Blonde","year":"2018","journal-title":"Adv Ther."},{"issue":"9","key":"pone.0311935.ref023","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/jama.2018.10136","article-title":"Real-world evidence and real-world data for evaluating drug safety and effectiveness","volume":"320","author":"J Corrigan-Curay","year":"2018","journal-title":"JAMA"},{"issue":"6","key":"pone.0311935.ref024","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1177\/2168479018764662","article-title":"The use of real-world evidence and data in clinical research and postapproval safety studies","volume":"52","author":"MJ Lamberti","year":"2018","journal-title":"Ther Innov Regul Sci"},{"key":"pone.0311935.ref025","author":"Guidelines for good pharmacoepidemiology practices (GPP)","journal-title":"International Society for Pharmacoepidemiology Web site."},{"key":"pone.0311935.ref026","article-title":"Prescribing information.","author":"Nulojix","year":"2021","journal-title":"Bristol-Myers Squibb"},{"issue":"2","key":"pone.0311935.ref027","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1046\/j.1523-1755.1999.00299.x","article-title":"The Banff 97 working classification of renal allograft pathology","volume":"55","author":"LC Racusen","year":"1999","journal-title":"Kidney Int"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0311935","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T15:09:37Z","timestamp":1736521777000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0311935"}},"subtitle":[],"editor":[{"given":"Catherine A.","family":"Brissette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0311935","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,10]]}}}